Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study

References

• Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11): 2386–2393. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol 2020;27(6): 423–429. doi:10.1097/MOH.0000000000000612.
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocyto clin penia (ITP). J Med 2017;6(2): 16. doi:10.3390/jcm6020016.
   Google Scholar
• Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EbioMedicine 2022;76: 103820. doi:10.1016/j.ebiom.2022.103820.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost 2020;46(3): 275–288. doi:10.1055/s-0039-1700512.
   PubMed Web of Science ®Google Scholar
• Meyer O, Richter H, Lebioda A, Schill M. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany. Hematology 2021;26(1): 697–708. doi:10.1080/16078454.2021.1974203.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol 2011;93(3): 329–335. doi:10.1007/s12185-011-0791-1.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee JH, Lee H, Kang B, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res 2017;155: 86–91. doi:10.1016/j.thromres.2017.05.010.
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124(22): 3308–3315. doi:10.1182/blood-2014-05-578336.
   PubMed Web of Science ®Google Scholar
• Cooper N, Ghanima W. Immune thrombocytopenia. New Engl J Med 2019;381(10): 945–955. doi:10.1056/NEJMcp1810479.
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Waleed Ghanima W, Godeau B, González-López TJ, Grainger J, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22): 3780–3817. doi:10.1182/bloodadvances.2019000812.
   PubMed Web of Science ®Google Scholar
• Cooper N. State of the art - how I manage immune thrombocytopenia. Brit J Haematol 2017;177(1): 39–54. doi:10.1111/bjh.14515.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22): 2237–2247. doi:10.1056/NEJMoa073275.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9664): 641–648. doi:10.1016/S0140-6736(09)60402-5.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610): 395–403. doi:10.1016/S0140-6736(08)60203-2.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363(20): 1889–1899. doi:10.1056/NEJMoa1002625.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161(3): 411–423. doi:10.1111/bjh.12260.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113(10): 2161–2171. doi:10.1182/blood-2008-04-150078.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10039): 45–54. doi:10.1016/S0140-6736(16)00279-8.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica 2019;104(11): 2283–2291. doi:10.3324/haematol.2018.202283.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118(1): 28–36. doi:10.1182/blood-2010-10-313908.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica 2019;104(6): 1112–1123. doi:10.3324/haematol.2018.212845.
   PubMed Web of Science ®Google Scholar
• Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 2021;81(11): 1285–1305. doi:10.1007/s40265-021-01553-7.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009;9(Suppl 3): S347–56. doi:10.3816/CLM.2009.s.034.
   PubMedGoogle Scholar
• Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther 2021;15: 2243–2268. doi:10.2147/DDDT.S299591.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355(16): 1672–1681. doi:10.1056/NEJMoa054626.
   PubMed Web of Science ®Google Scholar
• Harrison P. Platelet function analysis. Blood Rev 2005;19(2): 111–123. doi:10.1016/j.blre.2004.05.002.
   PubMed Web of Science ®Google Scholar
• Hummel J, Mckendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009;8(1): 38–49. doi:10.1002/pst.326.
   PubMed Web of Science ®Google Scholar
• Smith BP, Vandenhende FR, Desante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17(10): 1278–1283. doi:10.1023/a:1026451721686.
   PubMed Web of Science ®Google Scholar
• Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76(6): 628–638. doi:10.1016/j.clpt.2004.08.010.
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007;47(12): 1489–1497. doi:10.1177/0091270007306563.
   PubMed Web of Science ®Google Scholar
• Yang BB, Doshi S, Arkam K, Franklin J, Chow AT. Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective. Clin Pharmacokinet 2016;55(9): 1045–1058. doi:10.1007/s40262-016-0382-7.
   PubMed Web of Science ®Google Scholar
• Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 2010;12(4): 729–740. doi:10.1208/s12248-010-9234-9.
   PubMed Web of Science ®Google Scholar